ProteoBridge Announces Third-Party Allotment to Strengthen Research Testing Services and Advance New Product Development

ProteoBridge Inc. is pleased to announce that it has successfully completed a third-party allotment of shares, raising 50.4 million yen, with Fushimi Pharmaceutical Co., Ltd. (Headquarters: Marugame City, Kagawa Prefecture; President: Toshiki Fushimi) as the allottee.
The proceeds from this financing will be utilized to further enhance the quality of our research testing services, including the A-Cube® Autoantibody Testing Service and the HuPEX® Comprehensive Protein Array Contract Analysis Service, while also accelerating the development of new products. Through these initiatives, ProteoBridge remains committed to driving innovation in the life sciences sector and to enhancing its corporate value.

Fushimi Pharmaceutical Co., Ltd. http://www.fushimi.co.jp/